Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Unicycive Therapeutics (Nasdaq: UNCY), a clinical-stage biotechnology company focused on kidney disease therapies, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's CEO, Shalabh Gupta, M.D., is scheduled to present on Monday, April 7, at 2:15 p.m. ET. Investors and interested parties can access both the live and archived webcast through the Events and Presentations section of the Unicycive website's Investor portal. One-on-one meetings with management can be arranged through Needham representatives.
Unicycive Therapeutics (Nasdaq: UNCY), un'azienda biotecnologica in fase clinica focalizzata sulle terapie per le malattie renali, ha annunciato la sua partecipazione alla 24ª Conferenza Virtuale Annuale di Needham sulla Salute.
Il CEO dell'azienda, Shalabh Gupta, M.D., è programmato per presentare lunedì 7 aprile alle 14:15 ET. Gli investitori e le parti interessate possono accedere sia alla diretta che alla registrazione del webcast attraverso la sezione Eventi e Presentazioni del portale per investitori del sito web di Unicycive. È possibile organizzare incontri individuali con il management tramite i rappresentanti di Needham.
Unicycive Therapeutics (Nasdaq: UNCY), una empresa biotecnológica en etapa clínica centrada en terapias para enfermedades renales, ha anunciado su participación en la 24ª Conferencia Virtual Anual de Salud de Needham.
El CEO de la compañía, Shalabh Gupta, M.D., está programado para presentar el lunes 7 de abril a las 2:15 p.m. ET. Los inversores y partes interesadas pueden acceder tanto a la transmisión en vivo como a la grabación a través de la sección de Eventos y Presentaciones del portal para inversores del sitio web de Unicycive. Se pueden organizar reuniones uno a uno con la dirección a través de los representantes de Needham.
유니사이브 테라퓨틱스 (Nasdaq: UNCY), 신장 질환 치료에 중점을 둔 임상 단계의 생명공학 회사가 제24회 니드햄 가상 헬스케어 컨퍼런스에 참여한다고 발표했습니다.
회사의 CEO인 샬라브 구프타, M.D.는 4월 7일 월요일 오후 2시 15분 ET에 발표할 예정입니다. 투자자와 관심 있는 당사자는 유니사이브 웹사이트의 투자자 포털 내 이벤트 및 발표 섹션을 통해 실시간 및 아카이브된 웹캐스트에 접근할 수 있습니다. 경영진과의 일대일 미팅은 니드햄 대표를 통해 조정할 수 있습니다.
Unicycive Therapeutics (Nasdaq: UNCY), une entreprise de biotechnologie en phase clinique axée sur les thérapies pour les maladies rénales, a annoncé sa participation à la 24e Conférence Virtuelle Annuelle de Needham sur la Santé.
Le PDG de l'entreprise, Shalabh Gupta, M.D., est prévu pour présenter le lundi 7 avril à 14h15 ET. Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct et à l'enregistrement via la section Événements et Présentations du portail des investisseurs du site web d'Unicycive. Des réunions individuelles avec la direction peuvent être organisées par l'intermédiaire des représentants de Needham.
Unicycive Therapeutics (Nasdaq: UNCY), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Therapien für Nierenerkrankungen konzentriert, hat seine Teilnahme an der 24. jährlichen virtuellen Gesundheitskonferenz von Needham bekannt gegeben.
Der CEO des Unternehmens, Shalabh Gupta, M.D., wird am Montag, den 7. April um 14:15 Uhr ET präsentieren. Investoren und Interessierte können sowohl auf den Live- als auch auf den archivierten Webcast über den Bereich Veranstaltungen und Präsentationen im Investorenportal der Unicycive-Website zugreifen. Einzelgespräche mit dem Management können über die Vertreter von Needham arrangiert werden.
- None.
- None.
LOS ALTOS, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, at 2:15 p.m. ET.
A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. To request a 1x1 meeting with management, please contact your Needham representative.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Positive pivotal trial results were reported in June 2024 for OLC, and a New Drug Application (NDA) is under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) Target Action Date of June 28, 2025. OLC is protected by a strong global patent portfolio including an issued patent on composition of matter with exclusivity until 2031, and with the potential patent term extension until 2035 after OLC approval. Unicycive’s second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. UNI-494 has successfully completed a Phase 1 trial. For more information, please visit Unicycive.com and follow us on LinkedIn, X, and YouTube.
Investor Contact:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Media Contact:
Rachel Visi
Real Chemistry
redery@realchemistry.com
SOURCE: Unicycive Therapeutics, Inc.
FAQ
When is Unicycive Therapeutics (UNCY) presenting at the Needham Healthcare Conference?
How can investors watch Unicycive's (UNCY) Needham Conference presentation?
What is the main focus of Unicycive Therapeutics (UNCY)?
How can investors schedule a one-on-one meeting with Unicycive (UNCY) management?
